India  

Moderna Sues Pfizer Over COVID Vaccine Patents

Video Credit: Wibbitz Top Stories - Duration: 01:30s - Published
Moderna Sues Pfizer Over COVID Vaccine Patents

Moderna Sues Pfizer Over COVID Vaccine Patents

Moderna Sues Pfizer , Over COVID Vaccine Patents.

Moderna Sues Pfizer , Over COVID Vaccine Patents.

AP reports that Moderna is suing Pfizer and BioNTech for allegedly copying its technology.

.

On Aug.

26, Moderna said the companies' vaccine, Comirnaty, infringes on patents filed years ago for its own vaccine, Spikevax.

.

On Aug.

26, Moderna said the companies' vaccine, Comirnaty, infringes on patents filed years ago for its own vaccine, Spikevax.

.

Stephane Bancel, Moderna CEO, claims the vaccine developer was first to create the mRNA technology used in the current vaccines.

.

Stephane Bancel, Moderna CEO, claims the vaccine developer was first to create the mRNA technology used in the current vaccines.

.

The company claims to have started developing the technology in 2010, which helped it to quickly manufacture its COVID vaccine.

The technology is vastly different from the way vaccines typically work.

.

AP reports that a Pfizer spokesperson said the company has yet to be served.

Moderna is not requesting for Comirnaty to be removed from the market because of the importance of vaccine access.

The company is also not trying to prevent future sales.

.

We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic.

, Stephane Bancel, Moderna CEO, via statement


You Might Like


💡 newsR Knowledge: Other News Mentions

Pfizer Pfizer American multinational pharmaceutical and biotechnology corporation

Pfizer and BioNTech Claim Omicron Booster Is Stronger Than Original Shot [Video]

Pfizer and BioNTech Claim Omicron Booster Is Stronger Than Original Shot

Pfizer and BioNTech Claim, Omicron Booster Is Stronger , Than Original Shot. The companies made the claim via a press release issued on Nov. 4. Based on two company-led studies, the results have not been confirmed by independent scientists. Pfizer and BioNTech claim the results show their booster vaccine can be up to four times more effective for adults over 55. As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible... , Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. ... in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.5 sublineages, Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. These updated data also provide confidence in the adaptability of our mRNA platform... , Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. ... and our ability to rapidly update the vaccine to match the most prevalent strains each season, Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. BioNTech's CEO stated that the companies will continue to tailor their vaccines to new COVID variants and subvariants. In the next step and as part of our science-based approach we will continue to evaluate the cross-neutralization of the adapted vaccine against new variants and sublineages. , Professor Ugur Sahin, BioNTech CEO and Co-founder, via Pfizer Press Release. Our goal is to provide broader immunity against COVID-19 caused by SARS-CoV-2, including Omicron and other circulating strains, Professor Ugur Sahin, BioNTech CEO and Co-founder, via Pfizer Press Release. According to the Pfizer press release, . ... the company has shared its data with both the U.S. Food and Drug Administration and the European Medicines Agency

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer To Increase US COVID Vaccine Price to $110–$130 per Dose [Video]

Pfizer To Increase US COVID Vaccine Price to $110–$130 per Dose

Pfizer To Increase US COVID Vaccine Price , to $110–$130 per Dose. Reuters reports that Pfizer executive Angela Lukin made the announcement on Oct. 20. . The new price range, which is nearly quadruple the current cost, will go into effect when the government's purchase program expires. Currently, the U.S. government pays Pfizer/BioNTech $30 per dose. Lukin expects that those who have either private or government-paid insurance will be able to continue to receive the vaccine at little or no cost. We are confident that the U.S. price point of the COVID-19 vaccine reflects its overall cost effectiveness and ensures the price will not be a barrier for access for patients, Angela Lukin, Pfizer executive, via Reuters. According to the CDC, the updated cost will be in line with other adult vaccinations. For example, hepatitis and shingles vaccines range from $13 to over $200. Reuters reports that since the COVID vaccine is no longer being administered in an "emergency" setting, demand isn't as high. Experts predict demand will soon be comparable to other annual vaccinations such as flu shots. Reuters reports that since COVID boosters have been updated to target Omicron strains, roughly 14.8 million Americans got boosted during the first six weeks of the rollout

Credit: Wibbitz Top Stories    Duration: 01:31Published

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

China relaxes Zero-Covid policy, cases might see a spike | Oneindia News *News [Video]

China relaxes Zero-Covid policy, cases might see a spike | Oneindia News *News

Covid-19 cases in China might spike again as the country has relaxed its controversial Zero-Covid policy after a massive protest by the people. #ChinaCovid-19 #ZeroCovidpolicy #CovidspikeinChina

Credit: Oneindia    Duration: 02:41Published
China announces nationwide loosening of Covid restrictions [Video]

China announces nationwide loosening of Covid restrictions

Credit: FRANCE 24 English    Duration: 01:42Published
China to ease quarantine, testing in nationwide loosening of Covid restrictions [Video]

China to ease quarantine, testing in nationwide loosening of Covid restrictions

Credit: FRANCE 24 English    Duration: 02:26Published

Covid on wane but doctors still bat for masks

Majority of people don’t prefer the mask, but health experts point out that it is still the best protection against Covid-19, flu and, at the moment in many..
IndiaTimes

BioNTech BioNTech German biotechnology company

Related news from verified sources

Moderna sues Pfizer, BioNTech over patent infringement of its Covid vaccine


newKerala.com - Published


Related videos from verified sources

Drs. Marik and McCullough on NewsMax: Moderna vs Pfizer Patent Lawsuit [Video]

Drs. Marik and McCullough on NewsMax: Moderna vs Pfizer Patent Lawsuit

Drs Paul Marik and Dr. Peter McCullough were guests on Wake Up America with Amanda Brilhante and Carl Higbie. They covered the news of the Moderna versus Pfizer patent lawsuit over the COVID-19..

Credit: Rumble     Duration: 05:20Published
Moderna sues Pfizer, BioNTech over COVID vaccine patent [Video]

Moderna sues Pfizer, BioNTech over COVID vaccine patent

Credit: Rumble     Duration: 04:06Published
Moderna Sues Pfizer Over Covid Vaccine  The News [Video]

Moderna Sues Pfizer Over Covid Vaccine The News

Credit: Rumble     Duration: 00:49Published